[Antiandrogen strategies in prostate cancer: reconstitution of oestrogen receptor beta].
In advanced prostate cancer, albeit castration resistant, an active androgen receptor is still pivotal for growth and cell survival. Recent therapies involving more effective antiandrogens such as MDV3100 proved to be successful. Furthermore, blocking de novo intracrine androgen synthesis, e.g. with abiraterone acetate, provides additional benefit. Besides these antiandrogen measures, compounds which enable the reconstitution of the oestrogen receptor beta as a tumour suppressor restrain aberrant androgen receptor signalling.
Thelen
P
P
Urologische Universitätsklinik, Georg-August-Universität Göttingen, Robert-Koch-Strasse 40, 37075, Göttingen, Deutschland.
Strauss
A
A
Stettner
M
M
Kaulfuss
S
S
Ringert
R-H
RH
Loertzer
H
H
D000726:Androgen Antagonists / Q000008:administration & dosage*; D000818:Animals; D047629:Estrogen Receptor beta / Q000378:metabolism*; D006801:Humans; D008297:Male; D008954:Models, Biological; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects*; D015854:Up-Regulation / Q000187:drug effects
D000726:Androgen Antagonists; D047629:Estrogen Receptor beta